메뉴 건너뛰기




Volumn 30, Issue 6, 1996, Pages 463-481

Pharmacokinetic optimisation in the treatment of Parkinson's disease

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BIPERIDEN; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; ORPHENADRINE; PERGOLIDE; PROCYCLIDINE; SELEGILINE; TRIHEXYPHENIDYL;

EID: 0029972115     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630060-00004     Document Type: Review
Times cited : (71)

References (196)
  • 2
    • 0000905251 scopus 로고
    • Therapeutic strategies in Parkinson's disease
    • Jankovic J, Tolosa E, editors. Baltimore: Williams & Wilkins
    • Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1993: 115-44
    • (1993) Parkinson's Disease and Movement Disorders , pp. 115-144
    • Jankovic, J.1    Marsden, C.D.2
  • 3
    • 0029337643 scopus 로고
    • Pharmacokinetic optimisation of drug therapy in elderly patients
    • Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
    • (1995) Drugs Aging , vol.7 , pp. 10-18
    • Parker, B.M.1    Cusack, B.J.2    Vestal, R.E.3
  • 5
    • 0022551086 scopus 로고
    • Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography
    • Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60
    • (1986) J Neurol Neurosurg Psychiatry , vol.49 , pp. 853-860
    • Leenders, K.L.1    Palmer, A.J.2    Quinn, N.3
  • 6
    • 0026569502 scopus 로고
    • Cerebral uptake and utilization of therapeutic beta-11C-L-dopa in Parkinson's disease measured by positron emission tomography. Relations to motor response
    • Tedroff J, Aquilonius SM, Hartvig P, et al. Cerebral uptake and utilization of therapeutic beta-11C-L-dopa in Parkinson's disease measured by positron emission tomography. Relations to motor response. Acta Neurol Scand 1992; 85: 95-102
    • (1992) Acta Neurol Scand , vol.85 , pp. 95-102
    • Tedroff, J.1    Aquilonius, S.M.2    Hartvig, P.3
  • 7
    • 0028172598 scopus 로고
    • Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
    • Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36: 759-64
    • (1994) Ann Neurol , vol.36 , pp. 759-764
    • Vingerhoets, F.J.G.1    Snow, B.J.2    Lee, C.S.3
  • 8
    • 0023521931 scopus 로고
    • On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
    • Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535-40
    • (1987) Ann Neurol , vol.22 , pp. 535-540
    • Nutt, J.G.1
  • 9
    • 0016724743 scopus 로고
    • Intestinal decarboxylation of orally administered L-dopa
    • Andersson I, Granerus AK, Jagenburg R, et al. Intestinal decarboxylation of orally administered L-dopa. Acta Med Scand 1975; 198: 415-20
    • (1975) Acta Med Scand , vol.198 , pp. 415-420
    • Andersson, I.1    Granerus, A.K.2    Jagenburg, R.3
  • 10
    • 0017197009 scopus 로고
    • Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of Parkinsonism
    • Pinder RM, Brogden RN, Sawyer PR, et al. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of Parkinsonism. Drugs 1976; 11: 329-77
    • (1976) Drugs , vol.11 , pp. 329-377
    • Pinder, R.M.1    Brogden, R.N.2    Sawyer, P.R.3
  • 11
    • 0014467068 scopus 로고
    • Drug-induced changes of extracerebral dopa metabolism in man
    • Tissot R, Bartholini G, Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol 1969; 20: 187-90
    • (1969) Arch Neurol , vol.20 , pp. 187-190
    • Tissot, R.1    Bartholini, G.2    Pletscher, A.3
  • 12
    • 0024393058 scopus 로고
    • The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa
    • Robertson DRC, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmucol 1989; 28: 61-9
    • (1989) Br J Clin Pharmucol , vol.28 , pp. 61-69
    • Robertson, D.R.C.1    Wood, N.D.2    Everest, H.3
  • 13
    • 0018858058 scopus 로고
    • Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa
    • Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. Arch Neurol 1980; 37: 146-9
    • (1980) Arch Neurol , vol.37 , pp. 146-149
    • Hoehn, M.M.1
  • 14
    • 0022354407 scopus 로고
    • Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism
    • Bermejo Pareja F, Martinez-Martin P, Muradas V, et al. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism. Acta Neurol Scand 1985; 72: 506-11
    • (1985) Acta Neurol Scand , vol.72 , pp. 506-511
    • Bermejo Pareja, F.1    Martinez-Martin, P.2    Muradas, V.3
  • 15
    • 0022590163 scopus 로고
    • Effect of supplemental carbidopa on bioavailability of L-dopa
    • Cedarbaum JM, Kutt H, Dhar AK, et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986; 9: 153-9
    • (1986) Clin Neuropharmacol , vol.9 , pp. 153-159
    • Cedarbaum, J.M.1    Kutt, H.2    Dhar, A.K.3
  • 16
    • 0347206174 scopus 로고
    • Clinical studies of carbidopa and l-dopa in the treatment of Parkinson's disease
    • Yahr MD, editor. New York: Raven Press
    • Jaffe ME. Clinical studies of carbidopa and l-dopa in the treatment of Parkinson's disease. In: Yahr MD, editor. Advances in neurology. New York: Raven Press, 1973: 161-72
    • (1973) Advances in Neurology , pp. 161-172
    • Jaffe, M.E.1
  • 17
    • 0019156918 scopus 로고
    • Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease
    • Tourtellotte JW, Syndulko K, Potvin AR, et al. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease. Arch Neurol 1980; 37: 723-6
    • (1980) Arch Neurol , vol.37 , pp. 723-726
    • Tourtellotte, J.W.1    Syndulko, K.2    Potvin, A.R.3
  • 18
    • 0018639137 scopus 로고
    • Levodopa with benserazide or carbidopa in Parkinson disease
    • Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 1979; 29: 1584-9
    • (1979) Neurology , vol.29 , pp. 1584-1589
    • Rinne, U.K.1    Molsa, P.2
  • 19
    • 0028954916 scopus 로고
    • International guide to drugs for Parkinson's disease
    • Oertel WH, Dodel RC. International guide to drugs for Parkinson's disease. Mov Disord 1995; 10: 121-31
    • (1995) Mov Disord , vol.10 , pp. 121-131
    • Oertel, W.H.1    Dodel, R.C.2
  • 20
    • 0015922208 scopus 로고
    • Active transport of L-dopa in the intestine
    • Wade DN, Mearrick PT, Morris J. Active transport of L-dopa in the intestine. Nature 1973; 242: 463-5
    • (1973) Nature , vol.242 , pp. 463-465
    • Wade, D.N.1    Mearrick, P.T.2    Morris, J.3
  • 21
    • 0014940306 scopus 로고
    • L-dopa treatment failure: Explanation and correction
    • Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. L-dopa treatment failure: explanation and correction. BMJ 1970; 4: 93-4
    • (1970) BMJ , vol.4 , pp. 93-94
    • Rivera-Calimlim, L.1    Dujovne, C.A.2    Morgan, J.P.3
  • 22
    • 0021359568 scopus 로고
    • The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport
    • Nutt JG, Woodward WR, Hammerstad JP, et al. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310: 483-8
    • (1984) N Engl J Med , vol.310 , pp. 483-488
    • Nutt, J.G.1    Woodward, W.R.2    Hammerstad, J.P.3
  • 23
    • 0023522470 scopus 로고
    • Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients
    • Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37
    • (1987) Clin Neuropharmacol , vol.10 , pp. 527-537
    • Baruzzi, A.1    Contin, M.2    Riva, R.3
  • 24
    • 0017225588 scopus 로고
    • Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man
    • Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man. Eur J Clin Pharmacol 1976; 35: 293-9
    • (1976) Eur J Clin Pharmacol , vol.35 , pp. 293-299
    • Algeri, S.1    Cerletti, C.2    Curcio, M.3
  • 25
    • 0026070503 scopus 로고
    • Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: Effect on levodopa bioavailability
    • Contin M, Riva R, Martinelli P, et al. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: effect on levodopa bioavailability. Clin Neuropharmacol 1991; 14: 148-55
    • (1991) Clin Neuropharmacol , vol.14 , pp. 148-155
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 26
    • 0016743254 scopus 로고
    • Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man
    • Morgan JP, Rivera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029-34
    • (1975) Neurology , vol.25 , pp. 1029-1034
    • Morgan, J.P.1    Rivera-Calimlim, L.2    Messiha, F.3
  • 27
    • 0025888930 scopus 로고
    • Gastric emptying in healthy volunteers after multiple doses of levodopa
    • Waller DG, Roseveare C, Renwick AG, et al. Gastric emptying in healthy volunteers after multiple doses of levodopa. Br J Clin Pharmacol 1991; 32: 691-5
    • (1991) Br J Clin Pharmacol , vol.32 , pp. 691-695
    • Waller, D.G.1    Roseveare, C.2    Renwick, A.G.3
  • 28
    • 0023856314 scopus 로고
    • Lack of pharmacokinetic influence on levodopa by bromocriptine
    • Bentuè-Ferrer D, Allain H, Reymann JM, et al. Lack of pharmacokinetic influence on levodopa by bromocriptine. Clin Neuropharmacol 1988; 11: 83-6
    • (1988) Clin Neuropharmacol , vol.11 , pp. 83-86
    • Bentuè-Ferrer, D.1    Allain, H.2    Reymann, J.M.3
  • 29
    • 0026458576 scopus 로고
    • No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease
    • Contin M, Riva R, Martinelli P, et al. No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease. Clin Neuropharmacol 1992; 15: 505-8
    • (1992) Clin Neuropharmacol , vol.15 , pp. 505-508
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 30
    • 0025789844 scopus 로고
    • The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease
    • Rabey JM, Schwartz M, Graff E, et al. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 1991; 14: 514-22
    • (1991) Clin Neuropharmacol , vol.14 , pp. 514-522
    • Rabey, J.M.1    Schwartz, M.2    Graff, E.3
  • 31
    • 0027270391 scopus 로고
    • Blood levodopa levels and Unified Parkinson's Disease Rating Scale function: With and without exercise
    • Goetz CG, Thelen JA, MacLeod CM, et al. Blood levodopa levels and Unified Parkinson's Disease Rating Scale function: with and without exercise. Neurology 1993; 43: 1040-2
    • (1993) Neurology , vol.43 , pp. 1040-1042
    • Goetz, C.G.1    Thelen, J.A.2    MacLeod, C.M.3
  • 32
    • 0026794991 scopus 로고
    • The effect of exercise on levodopa absorption
    • Carter JH, Nutt JG, Woodward WR. The effect of exercise on levodopa absorption. Neurology 1992; 42: 2042-5
    • (1992) Neurology , vol.42 , pp. 2042-2045
    • Carter, J.H.1    Nutt, J.G.2    Woodward, W.R.3
  • 34
    • 0025156924 scopus 로고
    • Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations
    • Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990; 13: 19-28
    • (1990) Clin Neuropharmacol , vol.13 , pp. 19-28
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 35
    • 0023185154 scopus 로고
    • Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients
    • Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 1987; 37: 940-4
    • (1987) Neurology , vol.37 , pp. 940-944
    • Gancher, S.T.1    Nutt, J.G.2    Woodward, W.R.3
  • 36
    • 0022397679 scopus 로고
    • The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa
    • Kaakkola S, Mannisto PT, Nissinen E, et al. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 1985; 72: 385-91
    • (1985) Acta Neurol Scand , vol.72 , pp. 385-391
    • Kaakkola, S.1    Mannisto, P.T.2    Nissinen, E.3
  • 37
    • 0026579830 scopus 로고
    • The influence of levodopa on gastric emptying in healthy elderly volunteers
    • Robertson DRC, Renwick AG, Macklin B, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. Eur J Clin Pharmacol 1992; 42: 409-12
    • (1992) Eur J Clin Pharmacol , vol.42 , pp. 409-412
    • Robertson, D.R.C.1    Renwick, A.G.2    Macklin, B.3
  • 38
    • 0028071369 scopus 로고
    • Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa
    • Verhagen Metman L, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 1994; 9: 463-5
    • (1994) Mov Disord , vol.9 , pp. 463-465
    • Verhagen Metman, L.1    Hoff, J.2    Mouradian, M.M.3
  • 39
    • 0022556678 scopus 로고
    • Inhibition of 1-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography
    • Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of 1-(18F) fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258-62
    • (1986) Ann Neurol , vol.20 , pp. 258-262
    • Leenders, K.L.1    Poewe, W.H.2    Palmer, A.J.3
  • 40
    • 0016425567 scopus 로고
    • Protein intake and treatment of Parkinson's disease with levodopa
    • Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975; 292: 181-4
    • (1975) N Engl J Med , vol.292 , pp. 181-184
    • Mena, I.1    Cotzias, G.C.2
  • 41
    • 0023141842 scopus 로고
    • Influence of dietary protein on motor fluctuations in Parkinson's disease
    • Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 1987; 44: 270-2
    • (1987) Arch Neurol , vol.44 , pp. 270-272
    • Pincus, J.H.1    Barry, K.2
  • 42
    • 0023433165 scopus 로고
    • Plasma levels of amino acids correlate with motor fluctuations in Parkinsonism
    • Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in Parkinsonism. Arch Neurol 1987; 44: 1006-9
    • (1987) Arch Neurol , vol.44 , pp. 1006-1009
    • Pincus, J.H.1    Barry, K.M.2
  • 43
    • 0025772989 scopus 로고
    • A balanced carbohydrate: Protein diet in the management of Parkinson's disease
    • Berry EM, Growdon JH, Wurtman JJ, et al. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991; 41: 1295-7
    • (1991) Neurology , vol.41 , pp. 1295-1297
    • Berry, E.M.1    Growdon, J.H.2    Wurtman, J.J.3
  • 44
    • 0003673876 scopus 로고
    • Washington, DC: National Academy Press
    • Committee on dietary allowances food and nutrition board, editor. Recommended dietary allowances. Washington, DC: National Academy Press, 1989
    • (1989) Recommended Dietary Allowances
  • 45
    • 0023429272 scopus 로고
    • Dietary influences on the antiparkinsonian response to levodopa
    • Juncos JL, Fabbrini G, Mouradian MM, et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987; 44: 1003-5
    • (1987) Arch Neurol , vol.44 , pp. 1003-1005
    • Juncos, J.L.1    Fabbrini, G.2    Mouradian, M.M.3
  • 47
    • 0016829492 scopus 로고
    • Catechol-O-methyl transferase: Pharmacological aspects and physiological role
    • Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206
    • (1975) Pharmacol Rev , vol.27 , pp. 135-206
    • Guldberg, H.C.1    Marsden, C.A.2
  • 48
    • 0015302499 scopus 로고
    • 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral l-dopa therapy of patients with Parkinson's disease
    • Sharpless NS, Muenter MD, Tyce GM, et al. 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral l-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 1972; 37: 359-69
    • (1972) Clin Chim Acta , vol.37 , pp. 359-369
    • Sharpless, N.S.1    Muenter, M.D.2    Tyce, G.M.3
  • 49
    • 0016686587 scopus 로고
    • Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine
    • Pilling JB, Baker J, Iversen LL, et al. Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine. J Neurol Neurosurg Psychiatry 1975; 38: 129-35
    • (1975) J Neurol Neurosurg Psychiatry , vol.38 , pp. 129-135
    • Pilling, J.B.1    Baker, J.2    Iversen, L.L.3
  • 50
    • 0016707704 scopus 로고
    • 3-O-methyldopa uptake and inhibition of l-dopa at the blood-brain barrier
    • Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of l-dopa at the blood-brain barrier. Life Sci 1975; 17: 131-6
    • (1975) Life Sci , vol.17 , pp. 131-136
    • Wade, L.A.1    Katzman, R.2
  • 51
    • 0019985169 scopus 로고
    • 3-O-methyldopa blocks dopa metabolism in rat corpus striatum
    • Reches A, Fahn S. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 1982; 12: 267-71
    • (1982) Ann Neurol , vol.12 , pp. 267-271
    • Reches, A.1    Fahn, S.2
  • 52
    • 0020685128 scopus 로고
    • Effects of 3-OM-dopa on monoamine metabolism in rat brain
    • Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983; 33: 278-82
    • (1983) Neurology , vol.33 , pp. 278-282
    • Gervas, J.J.1    Muradas, V.2    Bazan, E.3
  • 53
    • 0023265840 scopus 로고
    • 3-O-methyldopa and the response to levodopa in Parkinson's disease
    • Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8
    • (1987) Ann Neurol , vol.21 , pp. 584-588
    • Nutt, J.G.1    Woodward, W.R.2    Gancher, S.T.3
  • 54
    • 0026724717 scopus 로고
    • 3-O-methyldopa administration does not alter fluorodopa transport into the brain
    • Guttman M, Leger G, Cedarbaum JM, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 1992; 31: 638-43
    • (1992) Ann Neurol , vol.31 , pp. 638-643
    • Guttman, M.1    Leger, G.2    Cedarbaum, J.M.3
  • 55
    • 0024521415 scopus 로고
    • Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet
    • Nelson MV, Berchou RC, Lewitt PA, et al. Pharmacokinetic and pharmacodynamic modeling of l-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol 1989; 12: 91-7
    • (1989) Clin Neuropharmacol , vol.12 , pp. 91-97
    • Nelson, M.V.1    Berchou, R.C.2    Lewitt, P.A.3
  • 56
    • 0025000599 scopus 로고
    • Pharmacokinetics and effects of levodopa in advanced Parkinson's disease
    • Bredberg E, Tedroff J, Aquilonius SM, et al. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990; 39: 385-9
    • (1990) Eur J Clin Pharmacol , vol.39 , pp. 385-389
    • Bredberg, E.1    Tedroff, J.2    Aquilonius, S.M.3
  • 57
    • 0025988169 scopus 로고
    • Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease
    • Contin M, Riva R, Martinelli P, et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 463-6
    • (1991) Eur J Clin Pharmacol , vol.41 , pp. 463-466
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 58
    • 0025149525 scopus 로고
    • Sinemet-ferrous sulphate interaction in patients with Parkinson's disease
    • Campbell NRC, Rankine D, Goodridge AE, et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605
    • (1990) Br J Clin Pharmacol , vol.30 , pp. 599-605
    • Campbell, N.R.C.1    Rankine, D.2    Goodridge, A.E.3
  • 59
    • 0015043830 scopus 로고
    • L-dopa therapy of Parkinson's disease: Plasma l-dopa concentration, therapeutic response, and side effects
    • Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma l-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231-9
    • (1971) Mayo Clin Proc , vol.46 , pp. 231-239
    • Muenter, M.D.1    Tyce, G.M.2
  • 60
    • 0020059227 scopus 로고
    • Alternate day levodopa therapy in parkinsonism
    • Koller WC. Alternate day levodopa therapy in parkinsonism. Neurology 1982; 32: 324-6
    • (1982) Neurology , vol.32 , pp. 324-326
    • Koller, W.C.1
  • 61
    • 0027212443 scopus 로고
    • Oral pulse levodopa therapy in mild Parkinson's disease
    • Quattrone A, Zappia M. Oral pulse levodopa therapy in mild Parkinson's disease. Neurology 1993; 43: 1161-6
    • (1993) Neurology , vol.43 , pp. 1161-1166
    • Quattrone, A.1    Zappia, M.2
  • 62
    • 0026466318 scopus 로고
    • Optimization of levodopa therapy
    • Pfeiffer R. Optimization of levodopa therapy. Neurology 1992: 42 Suppl. 1; 39-43
    • (1992) Neurology , vol.42 , Issue.1 SUPPL. , pp. 39-43
    • Pfeiffer, R.1
  • 63
    • 0026466358 scopus 로고
    • Initiating treatment of Parkinson's disease
    • Koller WC. Initiating treatment of Parkinson's disease. Neurology 1992; 42 Suppl. 1; 33-8
    • (1992) Neurology , vol.42 , Issue.1 SUPPL. , pp. 33-38
    • Koller, W.C.1
  • 64
    • 0001205759 scopus 로고
    • Practical guidelines for the drug treatment of Parkinson's disease
    • Mizuno Y, Mori H, Kondo T. Practical guidelines for the drug treatment of Parkinson's disease. CNS Drugs 1994; 1: 410-26
    • (1994) CNS Drugs , vol.1 , pp. 410-426
    • Mizuno, Y.1    Mori, H.2    Kondo, T.3
  • 65
    • 0027930341 scopus 로고
    • Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease
    • Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994; 44: 1287-92
    • (1994) Neurology , vol.44 , pp. 1287-1292
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 66
    • 0029982987 scopus 로고    scopus 로고
    • Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease
    • Contin M, Riva R, Martinelli P, et al. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 1996; 46: 1055-8
    • (1996) Neurology , vol.46 , pp. 1055-1058
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 67
    • 0023127020 scopus 로고
    • Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
    • Fabbrini G, Juncos JL, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987; 21: 370-6
    • (1987) Ann Neurol , vol.21 , pp. 370-376
    • Fabbrini, G.1    Juncos, J.L.2    Mouradian, M.M.3
  • 68
    • 0022443805 scopus 로고
    • Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
    • Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986; 36: 739-44
    • (1986) Neurology , vol.36 , pp. 739-744
    • Nutt, J.G.1    Woodward, W.R.2
  • 69
    • 0022657221 scopus 로고
    • Episodic unresponsiveness to single doses of l-dopa in parkinsonian fluctuators
    • Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of l-dopa in parkinsonian fluctuators. Neurology 1986; 36: 100-3
    • (1986) Neurology , vol.36 , pp. 100-103
    • Melamed, E.1    Bitton, V.2    Zelig, O.3
  • 70
    • 0023869464 scopus 로고
    • Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility
    • Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology 1988; 38: 419-21
    • (1988) Neurology , vol.38 , pp. 419-421
    • Kurlan, R.1    Kp, R.2    Woodward, W.R.3
  • 71
    • 0027159879 scopus 로고
    • Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: A pilot study
    • Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
    • (1993) Neurology , vol.43 , pp. 1036-1039
    • Kurth, M.C.1    Tetrud, J.W.2    Irwin, I.3
  • 72
    • 0026476554 scopus 로고
    • The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease
    • Steiger MJ, Stocchi F, Bramante L, et al. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol 1992; 15: 501-4
    • (1992) Clin Neuropharmacol , vol.15 , pp. 501-504
    • Steiger, M.J.1    Stocchi, F.2    Bramante, L.3
  • 73
    • 0028937547 scopus 로고
    • Madopar dispersible in the treatment of advanced parkinson's disease
    • Fornadi F, Milani F, Werner M. Madopar dispersible in the treatment of advanced parkinson's disease. Clin Neuropharmacol 1994; 17 (3 Suppl.): 7S-15S
    • (1994) Clin Neuropharmacol , vol.17 , Issue.3 SUPPL.
    • Fornadi, F.1    Milani, F.2    Werner, M.3
  • 74
    • 0028878429 scopus 로고
    • The effects of cisapride on plasma l-dopa levels and clinical response in Parkinson's disease
    • Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma l-dopa levels and clinical response in Parkinson's disease. Mov Disord 1995; 10: 66-70
    • (1995) Mov Disord , vol.10 , pp. 66-70
    • Neira, W.D.1    Sanchez, V.2    Mena, M.A.3
  • 75
    • 0028981463 scopus 로고
    • Effect of cisapride on response fluctuations in Parkinson's disease
    • Djaldetti R, Koren M. Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995; 10: 81-4
    • (1995) Mov Disord , vol.10 , pp. 81-84
    • Djaldetti, R.1    Koren, M.2    Ziv, I.3
  • 76
    • 0024507807 scopus 로고
    • Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease
    • Carter JH, Nutt JG, Woodward WR, et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1989; 39: 552-6
    • (1989) Neurology , vol.39 , pp. 552-556
    • Carter, J.H.1    Nutt, J.G.2    Woodward, W.R.3
  • 77
    • 0023845228 scopus 로고
    • Protein redistribution diet restores motor function in patients with dopa-resistanl 'off' periods
    • Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistanl 'off' periods. Neurology 1988: 38: 481-3
    • (1988) Neurology , vol.38 , pp. 481-483
    • Pincus, J.H.1    Barry, K.2
  • 78
    • 0023765002 scopus 로고
    • Practical application of a low-protein diet for Parkinson's disease
    • Riley D, Lane AE. Practical application of a low-protein diet for Parkinson's disease. Neurology 1988; 38: 1026-31
    • (1988) Neurology , vol.38 , pp. 1026-1031
    • Riley, D.1    Lane, A.E.2
  • 79
    • 0028944514 scopus 로고
    • Clinical efficacy of a liquid formulation of Levodopa (Madopar Dispersible) in reversing afternoon 'off' periods in Parkinson's disease
    • Ziegler M, Ranoux D, de Recondo J. Clinical efficacy of a liquid formulation of Levodopa (Madopar Dispersible) in reversing afternoon 'off' periods in Parkinson's disease. Clin Neuropharmacol 1994; 17 (3 Suppl.): 21S-5S
    • (1994) Clin Neuropharmacol , vol.17 , Issue.3 SUPPL.
    • Ziegler, M.1    Ranoux, D.2    De Recondo, J.3
  • 80
    • 0017840794 scopus 로고
    • Onset and end-of-dose levodopa-induced dyskinesias
    • Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978; 35: 261-3
    • (1978) Arch Neurol , vol.35 , pp. 261-263
    • Lhermitte, F.1    Agid, Y.2    Signoret, J.L.3
  • 81
    • 0028006366 scopus 로고
    • An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias
    • Mark MH, Sage JI. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias. Ann Clin Lab Sci 1994; 24: 12-21
    • (1994) Ann Clin Lab Sci , vol.24 , pp. 12-21
    • Mark, M.H.1    Sage, J.I.2
  • 82
    • 0022446286 scopus 로고
    • L-dopa: How it may exacerbate parkinsonian symptoms
    • Paalzow GHM, Paalzow LK. L-dopa: how it may exacerbate parkinsonian symptoms. TIPS 1986; 9: 15-9
    • (1986) TIPS , vol.9 , pp. 15-19
    • Paalzow, G.H.M.1    Paalzow, L.K.2
  • 83
    • 0026472109 scopus 로고
    • Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease
    • Merello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 1024-6
    • (1992) J Neurol Neurosurg Psychiatry , vol.55 , pp. 1024-1026
    • Merello, M.1    Lees, A.J.2
  • 84
    • 0023729233 scopus 로고
    • Does an inhibitory action of levodopa contribute to motor fluctuations?
    • Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1553-7
    • (1988) Neurology , vol.38 , pp. 1553-1557
    • Nutt, J.G.1    Gancher, S.T.2    Woodward, W.R.3
  • 85
    • 0026765992 scopus 로고
    • Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease
    • Contin M, Riva R, Martinelli P, et al. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 1992; 7: 244-8
    • (1992) Mov Disord , vol.7 , pp. 244-248
    • Contin, M.1    Riva, R.2    Martinelli, P.3
  • 86
    • 0025355032 scopus 로고
    • Levodopa-induced dyskinesia: Review, observations, and speculations
    • Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-5
    • (1990) Neurology , vol.40 , pp. 340-345
    • Nutt, J.G.1
  • 87
    • 0025818385 scopus 로고
    • Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced Chorea
    • Sage JI, Mark MH, McHale DM, et al. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced Chorea. Ann Neurol 1991; 29: 623-8
    • (1991) Ann Neurol , vol.29 , pp. 623-628
    • Sage, J.I.1    Mark, M.H.2    McHale, D.M.3
  • 88
    • 0025321413 scopus 로고
    • Complex dystonia of Parkinson's disease: Clinical features and relation to plasma levodopa profile
    • McHale DM, Sage JI, Sonsalla PK, et al. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990; 13: 164-70
    • (1990) Clin Neuropharmacol , vol.13 , pp. 164-170
    • McHale, D.M.1    Sage, J.I.2    Sonsalla, P.K.3
  • 89
    • 0028211054 scopus 로고
    • Severe evening dyskinesias in advanced parkinson's disease: Clinical description, relation to plasma levodopa, and treatment
    • Zimmerman TR, Sage JI, Lang AE, et al. Severe evening dyskinesias in advanced parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Mov Disord 1994; 9: 173-7
    • (1994) Mov Disord , vol.9 , pp. 173-177
    • Zimmerman, T.R.1    Sage, J.I.2    Lang, A.E.3
  • 90
    • 0024347984 scopus 로고
    • Pathogenesis of dyskinesias in Parkinson's disease
    • Mouradian MM, Heuser JE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989; 25: 523-6
    • (1989) Ann Neurol , vol.25 , pp. 523-526
    • Mouradian, M.M.1    Heuser, J.E.2    Baronti, F.3
  • 91
    • 0016587362 scopus 로고
    • Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients
    • Shoulson I, Glaubiger GA, Chase TN. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144-8
    • (1975) Neurology , vol.25 , pp. 1144-1148
    • Shoulson, I.1    Glaubiger, G.A.2    Chase, T.N.3
  • 92
    • 0021211101 scopus 로고
    • Control of on/off phenomenon by continuous intravenous infusion of levodopa
    • Quinn N, Parkes D, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131-6
    • (1984) Neurology , vol.34 , pp. 1131-1136
    • Quinn, N.1    Parkes, D.2    Marsden, C.D.3
  • 93
    • 0021142576 scopus 로고
    • On-off fluctuations in Parkinson's disease
    • Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. Brain 1984; 107: 487-506
    • (1984) Brain , vol.107 , pp. 487-506
    • Hardie, R.J.1    Lees, A.J.2    Stern, G.M.3
  • 94
    • 0023938094 scopus 로고
    • Duodenal and gastric delivery of levodopa in Parkinsonism
    • Kurlan R, Natl JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol 1988; 23: 589-95
    • (1988) Ann Neurol , vol.23 , pp. 589-595
    • Kurlan, R.1    Natl, J.G.2    Woodward, W.R.3
  • 95
    • 0013685763 scopus 로고
    • Continuous duodenal infusions of levodopa: Plasma concentrations and motor fluctuations in Parkinson's disease
    • Sage JI, Schuh L, Heikkila RB, et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol 1988; 11: 36-44
    • (1988) Clin Neuropharmacol , vol.11 , pp. 36-44
    • Sage, J.I.1    Schuh, L.2    Heikkila, R.B.3
  • 96
    • 0024361116 scopus 로고
    • The promise and limitations of controlled-release oral levodopa administration
    • Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 1989; 12: 147-66
    • (1989) Clin Neuropharmacol , vol.12 , pp. 147-166
    • Cedarbaum, J.M.1
  • 97
    • 0024850458 scopus 로고
    • Pharmaceutical design and development of a Sinemet controlled-release formulation
    • Dempski RE, Scholtz EC, Oberholtzer HR, et al. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989; 39 Suppl. 2; 20-4
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 20-24
    • Dempski, R.E.1    Scholtz, E.C.2    Oberholtzer, H.R.3
  • 98
    • 0023639043 scopus 로고
    • The hydrodynamically balanced system: A novel principle of controlled drug release
    • Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Fur Neurol 1987; 27 Suppl. 2, 21-7
    • (1987) Fur Neurol , vol.27 , Issue.2 SUPPL. , pp. 21-27
    • Erni, W.1    Held, K.2
  • 99
    • 0024804838 scopus 로고
    • Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies
    • Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39 Suppl. 2; 25-37
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 25-37
    • Yeh, K.C.1    August, T.F.2    Bush, D.F.3
  • 100
    • 0024829604 scopus 로고
    • Controlled-release carbidopa/levodopa(Sinemet 50/200 CR4): Clinical and pharmacokinelic studies
    • LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa(Sinemet 50/200 CR4): clinical and pharmacokinelic studies. Neurology 1989; 39 Suppl. 2; 45-53
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 45-53
    • LeWitt, P.A.1    Nelson, M.V.2    Berchou, R.C.3
  • 101
    • 0023629560 scopus 로고
    • Bioavailability of L-dopa afler Madopar HBS administration in healthy volunteers
    • Crevoisier C, Hoevels H, Zurcher G, et al. Bioavailability of L-dopa afler Madopar HBS administration in healthy volunteers. Eur Neurol 1987; 27 Suppl. 1; 36-46
    • (1987) Eur Neurol , vol.27 , Issue.1 SUPPL. , pp. 36-46
    • Crevoisier, C.1    Hoevels, H.2    Zurcher, G.3
  • 102
    • 0023616070 scopus 로고
    • Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease
    • Marion MH, Stocchi F, Malcolm SL, et al. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol 1987; 27 Suppl. 1: 54-8
    • (1987) Eur Neurol , vol.27 , Issue.1 SUPPL. , pp. 54-58
    • Marion, M.H.1    Stocchi, F.2    Malcolm, S.L.3
  • 103
    • 0042461417 scopus 로고
    • Therapeutic advantages of sustained release levodopa formulations in Parkinson's disease
    • Hutton JT, Morris JL. Therapeutic advantages of sustained release levodopa formulations in Parkinson's disease. CNS Drugs 1994; 2: 110-9
    • (1994) CNS Drugs , vol.2 , pp. 110-119
    • Hutton, J.T.1    Morris, J.L.2
  • 104
    • 0028473764 scopus 로고
    • Initiating treatment for idiopathic parkinsonism
    • Calne DB. Initiating treatment for idiopathic parkinsonism. Neurology 1994; 44 (6 Suppl.). 19S-22S
    • (1994) Neurology , vol.44 , Issue.6 SUPPL.
    • Calne, D.B.1
  • 105
    • 0023694278 scopus 로고
    • Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations
    • Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology 1988; 38: 1143-6
    • (1988) Neurology , vol.38 , pp. 1143-1146
    • Goetz, C.G.1    Tanner, C.M.2    Shannon, K.M.3
  • 106
    • 0028085949 scopus 로고
    • Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients
    • Hammerstad JP, Woodward WR, Nutt JG, et al. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994; 17: 429-34
    • (1994) Clin Neuropharmacol , vol.17 , pp. 429-434
    • Hammerstad, J.P.1    Woodward, W.R.2    Nutt, J.G.3
  • 107
    • 0024847369 scopus 로고
    • A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet
    • Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet. Neurology 1989; 39 Suppl. 2; 38-44
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 38-44
    • Cedarbaum, J.M.1    Kutt, H.2    McDowell, F.H.3
  • 108
    • 0028898323 scopus 로고
    • Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation
    • Harder S, Baas H, Bergemann N, et al. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol 1995; 39: 39-44
    • (1995) Br J Clin Pharmacol , vol.39 , pp. 39-44
    • Harder, S.1    Baas, H.2    Bergemann, N.3
  • 109
    • 0024520481 scopus 로고
    • A double-blind, crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance
    • Cedarbaum JM, Hoey M, McDowell FH. A double-blind, crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989; 52: 207-12
    • (1989) J Neurol Neurosurg Psychiatry , vol.52 , pp. 207-212
    • Cedarbaum, J.M.1    Hoey, M.2    McDowell, F.H.3
  • 110
    • 0023634716 scopus 로고
    • Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid of the absorption on Madopar HBS in volunteers
    • Malcolm SL, Allen JG, Bird H, et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid of the absorption on Madopar HBS in volunteers. Eur Neurol 1987; 27 Suppl. 1; 28-35
    • (1987) Eur Neurol , vol.27 , Issue.1 SUPPL. , pp. 28-35
    • Malcolm, S.L.1    Allen, J.G.2    Bird, H.3
  • 111
    • 0025886192 scopus 로고
    • Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR)
    • Wilding IR, Hardy JG, Davis SS, et al. Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 1991; 14: 305-21
    • (1991) Clin Neuropharmacol , vol.14 , pp. 305-321
    • Wilding, I.R.1    Hardy, J.G.2    Davis, S.S.3
  • 112
    • 0024836303 scopus 로고
    • Controlled-release carbidopa/levodopu (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: Clinical and pharmacokinetic observations
    • Deleu D, Jacques M, Michotte Y, et al. Controlled-release carbidopa/levodopu (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology 1989; 39 Suppl. 2; 88-92
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 88-92
    • Deleu, D.1    Jacques, M.2    Michotte, Y.3
  • 113
    • 0026461370 scopus 로고
    • The use of Sinemet CR in the management of mild to moderate Parkinson's disease
    • Rodnitzky RL. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Neurology 1992; 42 Suppl. 1: 44-50
    • (1992) Neurology , vol.42 , Issue.1 SUPPL. , pp. 44-50
    • Rodnitzky, R.L.1
  • 114
    • 84951515357 scopus 로고
    • Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease
    • Mannisto PT. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994; 1: 172-9
    • (1994) CNS Drugs , vol.1 , pp. 172-179
    • Mannisto, P.T.1
  • 115
    • 0027935135 scopus 로고
    • General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransterase
    • Kaakkola S, Gordin A, Mannislo PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransterase. Gen Pharmacol 1994; 25: 813-24
    • (1994) Gen Pharmacol , vol.25 , pp. 813-824
    • Kaakkola, S.1    Gordin, A.2    Mannislo, P.T.3
  • 116
    • 0027445460 scopus 로고
    • Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with parkinson's disease
    • Myllyla VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with parkinson's disease. Eur J Clin Pharmacol 1993; 45: 419-23
    • (1993) Eur J Clin Pharmacol , vol.45 , pp. 419-423
    • Myllyla, V.V.1    Sotaniemi, K.A.2    Illi, A.3
  • 117
    • 0028286186 scopus 로고
    • Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
    • Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913-9
    • (1994) Neurology , vol.44 , pp. 913-919
    • Nutt, J.G.1    Woodward, W.R.2    Beckner, R.M.3
  • 118
    • 0028078890 scopus 로고
    • Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients
    • Kaakkola S, Teravainen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994; 44: 77-80
    • (1994) Neurology , vol.44 , pp. 77-80
    • Kaakkola, S.1    Teravainen, H.2    Ahtila, S.3
  • 119
    • 0028137620 scopus 로고
    • Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
    • Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 186-9
    • (1994) J Neurol Neurosurg Psychiatry , vol.57 , pp. 186-189
    • Merello, M.1    Lees, A.J.2    Webster, R.3
  • 120
    • 0027770982 scopus 로고
    • Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
    • Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685-8
    • (1994) Neurology , vol.44 , pp. 2685-2688
    • Roberts, J.W.1    Cora-Locatelli, G.2    Bravi, D.3
  • 121
    • 0029021182 scopus 로고
    • Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
    • Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995; 18: 258-65
    • (1995) Clin Neuropharmacol , vol.18 , pp. 258-265
    • Limousin, P.1    Pollak, P.2    Pfefen, J.P.3
  • 122
    • 0028979687 scopus 로고
    • Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: Correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement
    • Tohgi H, Abe T, Yamazaki K, et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192: 165-8
    • (1995) Neurosci Lett , vol.192 , pp. 165-168
    • Tohgi, H.1    Abe, T.2    Yamazaki, K.3
  • 123
    • 0027520391 scopus 로고
    • Current status of dopamine agonists in Parkinson's disease management
    • Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93
    • (1993) Drugs , vol.46 , pp. 384-393
    • Montastruc, J.L.1    Rascol, O.2    Senard, J.M.3
  • 124
    • 0025938996 scopus 로고
    • Antiparkinsonian dopamine agonists: A review of the pharmacokinetics and neuropharmacology in animals and humans
    • Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991; 3: 151-201
    • (1991) J Neural Transm Park Dis Dement Sect , vol.3 , pp. 151-201
    • Wachtel, H.1
  • 126
    • 0023775714 scopus 로고
    • Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation
    • Drewe J, Mazer N, Abisch E, et al. Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 1988; 35: 535-41
    • (1988) Eur J Clin Pharmacol , vol.35 , pp. 535-541
    • Drewe, J.1    Mazer, N.2    Abisch, E.3
  • 127
    • 0020522424 scopus 로고
    • Fate and disposition of bromocriptine in animals and man. Pt II: Absorption, elimination and metabolism
    • Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. Pt II: absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983; 8: 51-62
    • (1983) Eur J Drug Metab Pharmacokinet , vol.8 , pp. 51-62
    • Maurer, G.1    Schreier, E.2    Delaborde, S.3
  • 128
    • 0025931590 scopus 로고
    • The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine
    • Kopitar Z, Vrhovac B, Povsic L, et al. The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet 1991; 16: 177-81
    • (1991) Eur J Drug Metab Pharmacokinet , vol.16 , pp. 177-181
    • Kopitar, Z.1    Vrhovac, B.2    Povsic, L.3
  • 129
    • 0023809080 scopus 로고
    • Therapeutic applications of bromocriptine in endocrine and neurological diseases
    • Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67-82
    • (1988) Drugs , vol.36 , pp. 67-82
    • Ho, K.Y.1    Thorner, M.O.2
  • 130
    • 0021927474 scopus 로고
    • Pharmacokinetic interactions of the macrolide antibiotics
    • Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79
    • (1985) Clin Pharmacokinet , vol.10 , pp. 63-79
    • Ludden, T.M.1
  • 131
    • 0025324182 scopus 로고
    • Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine
    • Nelson MV, Berchou RC, Kareli D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694-7
    • (1990) Clin Pharmacol Ther , vol.47 , pp. 694-697
    • Nelson, M.V.1    Berchou, R.C.2    Kareli, D.3
  • 132
    • 0017033806 scopus 로고
    • Bromocriptine in Parkinsonism: Long-term treatment, dose response, and comparison with levodopa
    • Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976; 39: 1101-8
    • (1976) J Neurol Neurosurg Psychiatry , vol.39 , pp. 1101-1108
    • Parkes, J.D.1    Debono, A.G.2    Marsden, C.D.3
  • 133
    • 0020030491 scopus 로고
    • Bromocriptine: Low-dose therapy in Parkinson disease
    • Teychenne PF, Bergsrud D, Racy A, et al. Bromocriptine: low-dose therapy in Parkinson disease. Neurology 1982; 32: 577-83
    • (1982) Neurology , vol.32 , pp. 577-583
    • Teychenne, P.F.1    Bergsrud, D.2    Racy, A.3
  • 134
    • 0021827869 scopus 로고
    • Low-dose bromocriptine therapy in Parkinson's disease
    • Pfeiffer RF, Wilken K, Glaeske C, et al. Low-dose bromocriptine therapy in Parkinson's disease. Arch Neurol 1985; 42: 586-8
    • (1985) Arch Neurol , vol.42 , pp. 586-588
    • Pfeiffer, R.F.1    Wilken, K.2    Glaeske, C.3
  • 135
    • 0023032395 scopus 로고
    • Domperidone and Parkinson's disease
    • Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9: 517-32
    • (1986) Clin Neuropharmacol , vol.9 , pp. 517-532
    • Parkes, J.D.1
  • 136
    • 0018395712 scopus 로고
    • Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease
    • Agid Y, Pollak P, Bonnet AM, et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979; 1: 570-2
    • (1979) Lancet , vol.1 , pp. 570-572
    • Agid, Y.1    Pollak, P.2    Bonnet, A.M.3
  • 137
    • 0021274464 scopus 로고
    • Disposition of oral Lisuride in Parkinson's disease
    • Burns RS, Gopinathan G, Humpel M, et al. Disposition of oral Lisuride in Parkinson's disease. Clin Pharmacol Ther 1984; 35: 548-56
    • (1984) Clin Pharmacol Ther , vol.35 , pp. 548-556
    • Burns, R.S.1    Gopinathan, G.2    Humpel, M.3
  • 138
    • 0019467050 scopus 로고
    • Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level
    • Humpel M, Nieuweboer B, Hasan SH, et al. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level. Eur J Clin Pharmacol 1981; 20: 47-51
    • (1981) Eur J Clin Pharmacol , vol.20 , pp. 47-51
    • Humpel, M.1    Nieuweboer, B.2    Hasan, S.H.3
  • 140
    • 0025317247 scopus 로고
    • Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease
    • Langtry HD, Clissold SP. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506
    • (1990) Drugs , vol.39 , pp. 491-506
    • Langtry, H.D.1    Clissold, S.P.2
  • 141
  • 142
    • 0025880115 scopus 로고
    • Absorption of apomorphine by various routes in Parkinsonism
    • Gancher ST, Null JG, Woodward WR. Absorption of apomorphine by various routes in Parkinsonism. Mov Disord 1991; 6: 212-6
    • (1991) Mov Disord , vol.6 , pp. 212-216
    • Gancher, S.T.1    Null, J.G.2    Woodward, W.R.3
  • 143
    • 0024378094 scopus 로고
    • Peripheral pharmacokinetics of apomorphine in humans
    • Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-8
    • (1989) Ann Neurol , vol.26 , pp. 232-238
    • Gancher, S.T.1    Woodward, W.R.2    Boucher, B.3
  • 145
    • 0029002551 scopus 로고
    • Apomorphine pharmacokinetics in Parkinsonism alter intranasal and subcutaneous application
    • Sam E, Jeanjean AP, Maloteaux JM, et al. Apomorphine pharmacokinetics in Parkinsonism alter intranasal and subcutaneous application. Eur J Drug Metab Pharmacokinet 1995; 20: 27-33
    • (1995) Eur J Drug Metab Pharmacokinet , vol.20 , pp. 27-33
    • Sam, E.1    Jeanjean, A.P.2    Maloteaux, J.M.3
  • 146
    • 0025793247 scopus 로고
    • Intranasal apomorphine in Parkinson's disease
    • Kleedorfer B, Turjanski N, Ryan R, et al. Intranasal apomorphine in Parkinson's disease. Neurology 1991; 41: 761-2
    • (1991) Neurology , vol.41 , pp. 761-762
    • Kleedorfer, B.1    Turjanski, N.2    Ryan, R.3
  • 147
  • 148
    • 0026750666 scopus 로고
    • Intranasal apomorphine in parkinsonian on-off fluctuations
    • Van Laar T, Jansen ENH, Essink AWG, et al. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992; 49: 482-4
    • (1992) Arch Neurol , vol.49 , pp. 482-484
    • Van Laar, T.1    Jansen, E.N.H.2    Essink, A.W.G.3
  • 149
    • 0025888372 scopus 로고
    • Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations
    • Hughes AJ, Webster R, Bovingdon M, et al. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin Neuropharmacol 1991; 14: 556-61
    • (1991) Clin Neuropharmacol , vol.14 , pp. 556-561
    • Hughes, A.J.1    Webster, R.2    Bovingdon, M.3
  • 150
    • 0026009886 scopus 로고
    • Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease
    • Durif F, Jeanneau E, Serre-Deheauvais F, et al. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease. Eur J Clin Pharmacol 1991; 41: 493-4
    • (1991) Eur J Clin Pharmacol , vol.41 , pp. 493-494
    • Durif, F.1    Jeanneau, E.2    Serre-Deheauvais, F.3
  • 151
    • 0029018469 scopus 로고
    • Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories
    • Van Laar T, Jansen ENH, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10: 433-9
    • (1995) Mov Disord , vol.10 , pp. 433-439
    • Van Laar, T.1    Jansen, E.N.H.2    Neef, C.3
  • 153
    • 0027264828 scopus 로고
    • Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
    • Hughes AJ, Bishop S, Kleedorler B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-70
    • (1993) Mov Disord , vol.8 , pp. 165-170
    • Hughes, A.J.1    Bishop, S.2    Kleedorler, B.3
  • 154
  • 155
    • 0021687731 scopus 로고
    • Biperiden effects and plasma levels in volunteers
    • Hollmann M, Brode E, Greger G, et al. Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 1984; 27: 619-21
    • (1984) Eur J Clin Pharmacol , vol.27 , pp. 619-621
    • Hollmann, M.1    Brode, E.2    Greger, G.3
  • 156
    • 0022639883 scopus 로고
    • Pharmacokinetic and pharmacodynamic studies following intravenous and oral administration of the antiparkinsonian drug biperiden in normal subjects
    • Grimaldi R, Perucca E, Ruberto G, et al. Pharmacokinetic and pharmacodynamic studies following intravenous and oral administration of the antiparkinsonian drug biperiden in normal subjects. Eur J Clin Pharmacol 1986; 30: 735-7
    • (1986) Eur J Clin Pharmacol , vol.30 , pp. 735-737
    • Grimaldi, R.1    Perucca, E.2    Ruberto, G.3
  • 157
  • 158
    • 0021838295 scopus 로고
    • Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients
    • Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18: 35-40
    • (1985) Ann Neurol , vol.18 , pp. 35-40
    • Burke, R.E.1    Fahn, S.2
  • 159
    • 0020517955 scopus 로고
    • Comparaison pharmacoclinique de deux formes galeniques de trihexyphenidyle
    • Garbarg S, Devissaguet JP, Prost M, et al. Comparaison pharmacoclinique de deux formes galeniques de trihexyphenidyle. Encéphale 1983; IX: 167-74
    • (1983) Encéphale , vol.9 , pp. 167-174
    • Garbarg, S.1    Devissaguet, J.P.2    Prost, M.3
  • 160
    • 0029054209 scopus 로고
    • Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans
    • He H, McKay G, Wirshing B, et al. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. J Pharm Sci 1995; 84: 561-7
    • (1995) J Pharm Sci , vol.84 , pp. 561-567
    • He, H.1    McKay, G.2    Wirshing, B.3
  • 161
    • 0019774915 scopus 로고
    • Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloridein man
    • Labout JJM, Thijssen CT, Keijser GGJ, et al. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloridein man. Eur J Clin Pharmacol 1982; 21: 343-50
    • (1982) Eur J Clin Pharmacol , vol.21 , pp. 343-350
    • Labout, J.J.M.1    Thijssen, C.T.2    Keijser, G.G.J.3
  • 162
    • 0020554474 scopus 로고
    • Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-n-desmethylorphenadrine (Tofenacine) in the rat
    • Bast A, van Kemenade FAA, Savenije-Chapel EM, et al. Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-n-desmethylorphenadrine (Tofenacine) in the rat. Res Commun Chem Pathol Pharmacol 1983; 40: 391-403
    • (1983) Res Commun Chem Pathol Pharmacol , vol.40 , pp. 391-403
    • Bast, A.1    Van Kemenade, F.A.A.2    Savenije-Chapel, E.M.3
  • 163
    • 0024319135 scopus 로고
    • Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics
    • Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 1989; 35: 736-43
    • (1989) Mol Pharmacol , vol.35 , pp. 736-743
    • Reidy, G.F.1    Mehta, I.2    Murray, M.3
  • 165
    • 0015272059 scopus 로고
    • Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: A comparison of eight mammalian species
    • Squires RF. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972; 5: 355-70
    • (1972) Adv Biochem Psychopharmacol , vol.5 , pp. 355-370
    • Squires, R.F.1
  • 166
    • 0017594522 scopus 로고
    • Dopamine is a monoamine oxidase-B substrate in man
    • Glover V, Sandler M, Owen F, et al. Dopamine is a monoamine oxidase-B substrate in man. Nature 1977; 265: 80-1
    • (1977) Nature , vol.265 , pp. 80-81
    • Glover, V.1    Sandler, M.2    Owen, F.3
  • 167
    • 0026841329 scopus 로고
    • Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms
    • Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms.' Neurology 1991; 42 Suppl. 4; 13-26
    • (1991) Neurology , vol.42 , Issue.4 SUPPL. , pp. 13-26
    • Olanow, C.W.1    Calne, D.2
  • 168
  • 169
    • 0010476575 scopus 로고
    • Pharmacokinetics of l-deprenyl and N-desmethyldeprenyl in blood versus plasma after single dose oral administration of 10 mg of selegiline
    • Michaelis K, Waitzinger J, Agvaz U, et al. Pharmacokinetics of l-deprenyl and N-desmethyldeprenyl in blood versus plasma after single dose oral administration of 10 mg of selegiline. Pharmacol Res 1993; 10: S331
    • (1993) Pharmacol Res , vol.10
    • Michaelis, K.1    Waitzinger, J.2    Agvaz, U.3
  • 170
    • 0022638352 scopus 로고
    • Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency
    • Yoshida T, Yamada Y, Yamamoto T, et al. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986; 16: 129-36
    • (1986) Xenobiotica , vol.16 , pp. 129-136
    • Yoshida, T.1    Yamada, Y.2    Yamamoto, T.3
  • 171
    • 0020085133 scopus 로고
    • Metabolism of (-) deprenyl to amphetamine and methamphetamme may be responsible for deprenyl's therapeutic benefit: A biochemical assessment
    • Karoum F, Chuang LW, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and methamphetamme may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 1982; 32: 503-9
    • (1982) Neurology , vol.32 , pp. 503-509
    • Karoum, F.1    Chuang, L.W.2    Eisler, T.3
  • 172
    • 0028593637 scopus 로고
    • Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies
    • Yasar S, Bergman J. Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 1994; 56: 768-73
    • (1994) Clin Pharmacol Ther , vol.56 , pp. 768-773
    • Yasar, S.1    Bergman, J.2
  • 173
    • 0023784118 scopus 로고
    • Deprenyl as symptomatic therapy in Parkinson's disease
    • Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11: 387-400
    • (1988) Clin Neuropharmacol , vol.11 , pp. 387-400
    • Golbe, L.I.1
  • 174
    • 0027981209 scopus 로고
    • Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal
    • Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal. Synapse 1994; 18: 86-93
    • (1994) Synapse , vol.18 , pp. 86-93
    • Fowler, J.S.1    Volkow, N.D.2    Logan, J.3
  • 176
    • 0025195904 scopus 로고
    • Possible interactions between deprenyl and Prozac
    • Suchowersky O, deVries J. Possible interactions between deprenyl and Prozac. Can J Neurol Sci 1990; 17: 352-3
    • (1990) Can J Neurol Sci , vol.17 , pp. 352-353
    • Suchowersky, O.1    DeVries, J.2
  • 177
    • 0027500494 scopus 로고
    • Pseudophaeo-chromocytoma in parkinsonian patient treated with fluoxetine plus selegiline
    • Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeo-chromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet 1993; 341: 555
    • (1993) Lancet , vol.341 , pp. 555
    • Montastruc, J.L.1    Chamontin, B.2    Senard, J.M.3
  • 179
    • 0025869797 scopus 로고
    • The serotonin syndrome
    • Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
    • (1991) Am J Psychiatry , vol.148 , pp. 705-713
    • Sternbach, H.1
  • 180
    • 0024456653 scopus 로고
    • Effect of deprenyl on the progression of disability in early Parkinson's disease
    • Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
    • (1989) N Engl J Med , vol.321 , pp. 1364-1371
  • 181
    • 0024343466 scopus 로고
    • The effect of deprenyl (selegiline) on the natural history of parkinson's disease
    • Tetrad JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of parkinson's disease. Science 1989; 245: 519-22
    • (1989) Science , vol.245 , pp. 519-522
    • Tetrad, J.W.1    Langston, J.W.2
  • 182
    • 0026596575 scopus 로고
    • Selegiline as initial treatment in de novo parkinsonian patients
    • Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339-43
    • (1992) Neurology , vol.42 , pp. 339-343
    • Myllyla, V.V.1    Sotaniemi, K.A.2    Vuorinen, J.A.3
  • 183
    • 0025189747 scopus 로고
    • L-deprenyl, levodopu pharmacokinetics, and response fluctuations in Parkinson's disease
    • Cedarbaum JM, Silvestri M, Clark M, et al. L-deprenyl, levodopu pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmaeol 1990; 13: 29-35
    • (1990) Clin Neuropharmaeol , vol.13 , pp. 29-35
    • Cedarbaum, J.M.1    Silvestri, M.2    Clark, M.3
  • 184
    • 84996113682 scopus 로고
    • Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis
    • Teychenne PF, Parker S. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis. Acta Neurol Scand 1989; 126: 119-25
    • (1989) Acta Neurol Scand , vol.126 , pp. 119-125
    • Teychenne, P.F.1    Parker, S.2
  • 185
    • 0026623522 scopus 로고
    • Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging
    • Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541-4
    • (1992) Neurology , vol.42 , pp. 541-544
    • Baronti, F.1    Davis, T.L.2    Boldry, R.C.3
  • 186
    • 0019124920 scopus 로고
    • Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa
    • Schachter M, Marsden CD, Parkes JD, et al. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980; 43: 1016-21
    • (1980) J Neurol Neurosurg Psychiatry , vol.43 , pp. 1016-1021
    • Schachter, M.1    Marsden, C.D.2    Parkes, J.D.3
  • 187
    • 0021852048 scopus 로고
    • The effect of L-deprenyl on on-off phenomena in Parkinson's disease
    • Brodersen P, Philbert A, Gulliksen G, et al. The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand 1985; 71: 494-7
    • (1985) Acta Neurol Scand , vol.71 , pp. 494-497
    • Brodersen, P.1    Philbert, A.2    Gulliksen, G.3
  • 188
    • 3242784708 scopus 로고
    • Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
    • Golbe LI, Lieherman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45-55
    • (1988) Clin Neuropharmacol , vol.11 , pp. 45-55
    • Golbe, L.I.1    Lieherman, A.N.2    Muenter, M.D.3
  • 189
    • 0026529661 scopus 로고
    • Deprenyl in Parkinson's disease: Mechanisms, neuroprolective effect, indications and adverse effects
    • Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprolective effect, indications and adverse effects. Can J Neurol Sci 1992; 19: 142-6
    • (1992) Can J Neurol Sci , vol.19 , pp. 142-146
    • Vezina, P.1    Mohr, E.2    Grimes, D.3
  • 190
    • 0014684012 scopus 로고
    • Amantadine in the treatment of Parkinson's disease
    • Schwah RS, England Jr AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208: 1168-70
    • (1969) JAMA , vol.208 , pp. 1168-1170
    • Schwah, R.S.1    England Jr., A.C.2    Poskanzer, D.C.3
  • 191
    • 0026005169 scopus 로고
    • N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease
    • Greenamyre JT, O'Brien CF. N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991; 48: 977-81
    • (1991) Arch Neurol , vol.48 , pp. 977-981
    • Greenamyre, J.T.1    O'Brien, C.F.2
  • 192
    • 0021795615 scopus 로고
    • Amantadine kinetics in healthy elderly men: Implications for influenza prevention
    • Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 1985; 37: 137-44
    • (1985) Clin Pharmacol Ther , vol.37 , pp. 137-144
    • Aoki, F.Y.1    Sitar, D.S.2
  • 193
    • 0019475566 scopus 로고
    • Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function
    • Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 94: 454-8
    • (1981) Ann Intern Med , vol.94 , pp. 454-458
    • Horadam, V.W.1    Sharp, J.G.2    Smilack, J.D.3
  • 194
    • 0021028081 scopus 로고
    • Amantadine-Dyazide interaction
    • Wilson TW, Rajput AH. Amantadine-Dyazide interaction. Can Med Assoc J 1983; 129: 974-5
    • (1983) Can Med Assoc J , vol.129 , pp. 974-975
    • Wilson, T.W.1    Rajput, A.H.2
  • 195
    • 0026353743 scopus 로고
    • Comparison of pharmacokinetic and safety profiles of amanladine 50- And 100-mg daily doses in elderly nursing home residents
    • Somani SK, Degelau J, Cooper SL, et al. Comparison of pharmacokinetic and safety profiles of amanladine 50- and 100-mg daily doses in elderly nursing home
    • (1991) Pharmacotherapy , vol.11 , pp. 460-466
    • Somani, S.K.1    Degelau, J.2    Cooper, S.L.3
  • 196
    • 0029019640 scopus 로고
    • Neuroprotective therapeutic strategies. Comparison of experimental and clinical results
    • Gerlach M, Riederer P, Youdim MBH. Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochem Pharmacol 1995; 50: 1-16
    • (1995) Biochem Pharmacol , vol.50 , pp. 1-16
    • Gerlach, M.1    Riederer, P.2    Youdim, M.B.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.